Bioquell's AOP Technology Highlighted at the HIS Conference 2014

Reducing wound bioburden through the use of aqueous oxygen peroxide (AOP) was one of the key topics highlighted at this years' November Healthcare Infection Society Conference in Lyon, France.

Wounds such as venous leg ulcers (VLUs) contain microorganisms. Often these organisms can evade or overwhelm a host's immune system leading to wound infection and wound chronicity. Produced from oxygen and water, AOP - more commonly known as aqueous ozone - is a powerful oxidising biocide that can be used on wounds as a lavage or 'wash'. This helps remove dead cells and infectious pathogens. It also provides a purified supply of aqueous ozone to the wound surface, boosting the potential oxygen supply to the damaged area.

The study was conducted in collaboration with a surgery in Winchester. Sixty one patients took part in the primary care-based, randomised, placebo-controlled trial (RCT). For two weeks, a selection of patients received sterile water placebo treatments whilst the rest were treated using novel BioxyQuell technology (which delivered a lavage at 20 parts per million AOP). In a further evaluation, four patients were treated with the BioxyQuell system.

The results showed that patients treated with the BioxyQuell technology had larger reductions in anaerobic (45.2% versus 20% of treatments), aerobic (42.9% versus 15% of treatments) and total wound bioburden (45.2% versus 15.6% of treatments, p=0.005).

Patients who underwent the treatment said, "This is a wonderful invention, we need more of it! I am worried about returning to my old clinic as I don't want my [venous leg] ulcer to deteriorate – it has done so well here", "I can only say that Trish [nurse] and BioxyQuell have done more to heal my wound in 8 weeks than the NHS has done in 2 years."

-Ends-

Resources: http://www.bioquell.com/en-uk/markets/wound-treatment/

For more information visit our website at www.bioquell.com.

Contact:

Marion Duguen, Marketing Coordinator

T: +44 (0)1264 835 886

E: marion.duguen@bioquell.com